Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 77,889 shares, a drop of 46.1% from the October 15th total of 144,402 shares. Based on an average daily volume of 77,098 shares, the short-interest ratio is presently 1.0 days. Approximately 7.4% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
BJDX has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, September 21st. Wall Street Zen cut shares of Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, September 14th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Bluejay Diagnostics presently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on BJDX
Bluejay Diagnostics Stock Performance
Shares of NASDAQ BJDX traded down $0.14 during mid-day trading on Tuesday, hitting $2.15. The stock had a trading volume of 13,734 shares, compared to its average volume of 531,305. Bluejay Diagnostics has a twelve month low of $1.84 and a twelve month high of $28.00. The firm has a market cap of $2.41 million, a PE ratio of -0.08 and a beta of 0.92. The company has a 50 day moving average of $3.05 and a two-hundred day moving average of $6.90.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($1.72) EPS for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.28.
About Bluejay Diagnostics
Bluejay Diagnostics is a medical diagnostics company focused on developing and commercializing tests for use in hospital and critical-care settings. Its products are intended to help clinicians assess patients with sepsis and other serious conditions. The company’s Symphony System is a diagnostic platform designed to measure biomarkers from blood samples. Its test portfolio has included assays for biomarkers such as interleukin-6 and procalcitonin, which can support the assessment of inflammation and infection.
Further Reading
- Five stocks we like better than Bluejay Diagnostics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
